A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

Clinical trial NCT00816023 · COMPLETED

Trial details

NCT number: NCT00816023
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Bloodloss Surgical Procedures, Operative

Start date: 2009-03-01
Primary completion: 2009-12-01
Enrollment: 276

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.